Mesothelioma
Advertisement
Deborah Brown shares key findings from the recently released seventh annual "State of Lung Cancer" report.
The campaign kicked off on November 1 to coincide with Lung Cancer Awareness Month.
Deborah Brown shares how the American Lung Association and its LUNG FORCE initiative are raising awareness this month.
Dr. Studts discusses why Lung Cancer Awareness Month is a critical time to inspire action, engagement, and hope.
The initiative is promoting lung cancer screening and efforts to fund research, as well as releasing an upcoming report.
Researchers conducted an extensive analysis of PM2.5 exposure based on residential history, satellite data, and more.
Lung Cancer Awareness Month is observed every November and represents a key time to take action and raise awareness.
The campaign, titled "Anyone with Lungs Can Get Lung Cancer," includes multiple virtual and in-person components.
Arthi Sridhar, MD, discusses the real-world study, which was presented at the IASLC 2024 World Conference on Lung Cancer.
Learn what the global survey showed about the rates of biomarker testing and the remaining barriers to implementation.
Michael R. Gieske, MD, discusses the lung cancer screening initiative, which has been recognized on a national level.
The registry, launched by the Florez Lab in 2023, is collecting data from around the world.
Indoor air pollutants can come from multiple sources and can be risk factors for developing lung cancer.
Shirish M. Gadgeel, MD, shares how treatment options and patient outcomes have evolved since he began practicing.
Dr. Gieske shares what the White Ribbon Project means to him as a lung cancer clinician.
Researchers presented results from the randomized controlled trial of mPATH-Lung at the CHEST Annual Meeting.
Jamie L. Studts, PhD, discusses the use of the QUILS™ system in Kentucky and the importance of community engagement.
Annette McWilliams, MBBS, FRACP, PhD, discusses her IASLC Presidential Symposium presentation on the study.
Jill Feldman, a patient advocate, discusses how the lexicon can improve communication and empower patients.
The KEYNOTE-483 trial showed a significant improvement in OS with the addition of pembrolizumab to chemotherapy.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.